药物名称：YH002（OX40)

阶段：临床I期

适应症：实体瘤

开展地区：澳大利亚

试验名称：A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects with Advanced Solid Malignancies

试验链接：https://clinicaltrials.gov/ct2/show/NCT04353102